Key Developments For Plexus Corp.
Plexus Corp. (PLXS.O) (Nasdaq)
Plexus Corp. Issues Q1 2010 Guidance; EPS Guidance Above Analysts' Estimates
Plexus Corp. announced that for first quarter of 2010, the Company expects revenue of $405-$430 million, diluted earnings per share (EPS) of $0.31-$0.36, excluding any restructuring charges and including approximately $0.05 per share of stock-based compensation expense. According to Reuters Estimates, analysts were expecting the Company to report revenues of $411 million and EPS of $0.29 for the same period.
Plexus Corp. Issues Q4 2009 Outlook
Plexus Corp. announced that for the fourth quarter of 2009, it expects revenue to be in the range of $380 million to $405 million and diluted EPS to be in the range of $0.27 to $0.32, excluding any restructuring charges and including approximately $0.04 per share of stock-based compensation expense. According to Reuters Estimates, analysts on an average are expecting the Company to report revenue of $389 million and earnings per share (EPS) of $0.27 for the fourth quarter of 2009.
Plexus Corp. Announces Manufacturing Agreement With The Coca-Cola Company
Plexus Corp. announced that it is partnering with The Coca-Cola Company to manufacture Coca-Cola Freestyle, a new fountain dispenser that utilizes technology to dispense more than 100 different branded sparkling and still beverages from a single freestanding unit. The Coca-Cola Company will leverage Plexus' global supply chain, manufacturing solutions and expertise in engineering services to bring this product to market. Plexus referenced this program as a new confidential mechatronics win in its 2008 fiscal year-end earnings press release.
Plexus Corp. To Reaffirm Q3 2009 Guidance
Plexus Corp. announced that for third quarter of 2009, it will confirm revenue from $355-$385 million and earrings per share (EPS), excluding any restructuring or similar charges, in the range of $0.18-$0.25, including approximately $0.04 per share of stock based compensation expense. According to Reuters Estimates, analysts on average are expecting the Company to report revenue of $373 million; EPS of $0.23 for the same period.
Plexus Corp. Announces Development Contract With QIAGEN
Plexus Corp. announced that it has been selected to develop QIAGEN's automated screening system for the pre-processing of human papillomavirus (HPV) DNA samples. This contract for the final development phase builds on the existing collaboration which led to the first prototypes.
